ClinicalTrials.gg
CompletedNCT06370039Updated Sep 18, 2026

Study of INV-102 Ophthalmic Solution in Adults With Moderate to Severe Dry Eye Disease

A Phase 2 interventional study of INV-102 and Vehicle in Dry Eye Disease, sponsored by Invirsa, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by Invirsa, Inc. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Jul 2024, 2 years 4 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Jun 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
109
Allocation
Randomized
Ages
18 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 544 studies in Dry Eye Syndromes with a site in United States — 52 open to participants now, 63 under way, 3 of them phase 3. Dry Eye Syndromes · United States.

Enrollment
170th of 473
109 · median 60
Started
2024
with 31 others
Phase 2
97 of 544
5 open now
Registered
462nd of 544
by date

Among the 544 studies in Dry Eye Syndromes with a site in United States, this one is the 170th largest by enrollment of the 473 interventional ones that give a count, is one of 32 that started in 2024, is one of 97 in phase 2, and was the 462nd registered.

Dry Eye Syndromes

1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

52 of the 544 studies in Dry Eye Syndromes with a site in United States are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 544 studies in Dry Eye Syndromes with a site in United States, or all of them as a file.
02

Study summary

Phase 2 study to assess the efficacy of topically administered eyedrops of INV-102 during 4-week repeat dosing in subjects with moderate to severe dry eye disease.

03

Conditions studied

  • Dry Eye Disease

Keywords

  • Dry Eye
  • Keratoconjunctivitis sicca
04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Subjects ≥18 and \<75 years of age
  • Presence of moderate to severe dry eye disease (DED) in at least one eye

Key Exclusion Criteria:

  • Presently using prescription eyedrops, except those used for dry eye disease, which must be discontinued 4 weeks prior
  • Use of over-the-counter (OTC) eyedrops except for lubricant eyedrops or artificial tears, within 1 week prior to initiation of study drug dosing
  • History or evidence of ocular infection within the previous 30 days
  • Blepharitis or meibomian gland disease requiring the use of either topical or systemic antibiotics within 2 months
  • Allergic conjunctivitis requiring treatment within 30 days
  • Unable to discontinue contact lens wear for 2 weeks prior and for the duration of the study
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
109 participants (actual)

Study arms

  • Experimental
    INV-102

    INV-102 0.7% ophthalmic solution administered for 4 weeks (twice daily \[BID\] for 2 weeks, then once daily \[QD\] for an additional 2 weeks)

    Drug: INV-102

  • Placebo comparator
    Vehicle

    Vehicle ophthalmic solution administered for 4 weeks (BID for 2 weeks, then QD for an additional 2 weeks)

    Drug: Vehicle

Interventions

  • INV-102 Ophthalmic Solution

  • DrugVehicle

    Vehicle Ophthalmic Solution

06

What researchers measure

Primary outcomes

  1. Change from Baseline in corneal fluorescein staining total score on the National Eye Institute (NEI)/Industry scale

    Corneal fluorescein staining assessment will be performed using the NEI grading system to score each of 5 corneal zones (central, superior, lateral, medial, inferior) on a 0 to 3 scale (with a total score of 0 to 15). Higher scores indicate more corneal damage.

    Time frame: Baseline to Day 29

Secondary outcomes

  1. Percentage of eyes with complete clearing of central corneal fluorescein staining

    Time frame: Baseline to Day 29

07

Study locations

1 site
  • iuvo BioScience
    Rush, New York 14543, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Jul 2024, 3 months.

Of 75 industry-sponsored phase 2 interventional studies under Dry Eye Syndromes, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 11. This study's 3 months is below that.

Counting every sponsor, half of 91 studies reached it within 7 months; a quarter within 5 and three quarters within 12.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2024
First posted
Apr 17, 2024
StartActual
Mar 27, 2024
Primary completionActual
Jul 3, 2024
CompletionActual
Jul 3, 2024
Results delay requested
Jun 27, 2025
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06370039
Lead sponsor
Invirsa, Inc.
Collaborators
Biomedical Advanced Research and Development Authority
Responsible party
Sponsor
First posted
Apr 17, 2024
Start date
Mar 27, 2024
Primary completion
Jul 3, 2024
Completion
Jul 3, 2024
Last update
Sep 18, 2026

Study contacts

Robert Shalwitz, MD
study chair · Invirsa, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: INV-102

Start the discussion